Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world - Takeaways - MDSpire

Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world

  • By

  • Pan Cheng

  • Jianjuan Ge

  • Shuangjia Huang

  • Dongzan Yang

  • Shining Xie

  • Bowen Wang

  • Zhaoshi Bai

  • Jichen He

  • Xiaolin Liu

  • May 20, 2026

  • 0 min

Share

  • 1

    Disitamab vedotin (RC48) demonstrated an objective response rate of 10.3% and a disease control rate of 63.8% in advanced gastric cancer patients.

  • 2

    The median progression-free survival for patients treated with RC48 was 4.2 months, with a 1-year progression-free survival rate of 13.0%.

  • 3

    Patients receiving RC48 as third-line therapy had a significantly higher disease control rate compared to those receiving it later (75.0% vs. 50.0%).

  • 4

    Common adverse drug reactions included neutropenia, hemoglobin reduction, and liver impairment, with 17.2% experiencing grade III or higher ADRs.

  • 5

    The study concluded that RC48 has a manageable safety profile and some clinical efficacy in real-world settings for HER2-expressing advanced gastric cancer.

Original Source(s)

Efficacy and safety of disitamab vedotin in treatment of advanced gastric cancer based on real-world

  • by Pan Cheng, Jianjuan Ge, Shuangjia Huang, Dongzan Yang, Shining Xie, Bowen Wang, Zhaoshi Bai, Jichen He, Xiaolin Liu

  • May 20, 2026

Related Content

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Potential targets for boron transport in boron neutron capture therapy

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases